Tag Archives: Prometax

Alzheimer’s Disease Therapies

Current Therapies for Alzheimer’s Disease Because there is currently no cure for Alzheimer’s disease (), the primary goal of treatment remains the relief of cognitive, functional, and behavioral symptoms associated with the disease. Hence, current therapies aim to improve the quality of life for both Alzheimer’s disease patients and the caregivers who often must cope… Read More »

Alzheimer’s Therapy: Acetylcholinesterase Inhibitors

Overview. Acetylcholinesterase inhibitors are the only drugs approved for the treatment of mild to moderate Alzheimer’s disease in the major markets. acetylcholinesterase inhibitors do not cure Alzheimer’s disease but do alleviate the cholinergic deficit observed in Alzheimer’s disease patients. Cognitive symptoms are occasionally improved but most often are only stabilized by the drugs (). Studies… Read More »

 Alzheimer’s Therapy: Rivastigmine

Rivastigmine (Novartis’s Exelon, Sigma Tau/Esteve’s Prometax) () is available in Europe and the United States, where it is indicated for mild to moderate Alzheimer’s disease. Development of rivastigmine in Japan has been discontinued. Novartis is evaluating rivastigmine for the treatment of moderate to severe Alzheimer’s disease in small clinical trials, although it is unclear if… Read More »

Schizophrenia: Acetylcholinesterase Inhibitors

Three acetylcholinesterase inhibitors are on the market for the treatment of Alzheimer’s disease: Japan&Japan/Shire/Janssen’s galantamine (Reminyl), Eisai/Pfizer’s donepezil (Aricept), and Novartis’s rivastigmine (Exelon/Prometax). Clinical studies evaluating these agents in the treatment of the cognitive dysfunction and negative symptoms associated with schizophrenia have been performed, but only galantamine appears to be in commercial development for schizophrenia… Read More »